Profile: Aastrom Biosciences Inc (ASTM.O)

ASTM.O on Consolidated Issue listed on NASDAQ Capital Market

3.28USD
22 Jul 2014
Price Change (% chg)

$0.10 (+3.14%)
Prev Close
$3.18
Open
$3.21
Day's High
$3.34
Day's Low
$3.21
Volume
76,649
Avg. Vol
213,517
52-wk High
$17.79
52-wk Low
$3.09

Search Stocks

Aastrom Biosciences, Inc. (Aastrom), incorporated on March 24, 1989, is a development-stage company. The Company is a regenerative medicine company focused on the development of cell therapies to repair or regenerate damaged or diseased tissues. The Company is developing patient-specific, expanded multicellular therapies for use in the treatment of severe, chronic ischemic cardiovascular diseases. The Company’s cell-manufacturing technology enables the manufacture of multicellular therapies, expanded from an adult patient’s own bone marrow, to be delivered directly to damage tissues. In March 2013, it announced strategic change in research and development programs to focus on the clinical development of lead product, ixmyelocel-T, for the treatment of dilated cardiomyopathy (DCM). In June 2014, the Company acquired Sanofi's cell therapy and regenerative medicine (CTRM) business unit.

Ixmyelocel-T is a patient-specific, expanded multicellular therapy developed using the Company’s, automated processing system. Ixmyelocel-T is a product derived from an adult patient’s own bone marrow but it is enhanced compared with the original bone marrow. The Company’s process enhances the patient’s bone marrow mononuclear cells by expanding the mesenchymal stromal cells and M2 anti-inflammatory macrophages while retaining many of the hematopoietic cells. These cell types, known to regulate the immune response, are important in the resolution of pathologic inflammation and tissue repair. The manufacture of its patient-specific, expanded multicellular therapies is done under current Good Manufacturing Practices (cGMP) and current Good Tissue Practices (cGTP) guidelines required by the United States Food and Drug Administration (FDA). The Company’s development programs are focused on addressing areas of high unmet medical needs in severe, chronic ischemic cardiovascular diseases. The Company operates a centralized cell manufacturing facility in Ann Arbor, Michigan.

The Company competes with Baxter International, Inc, Biomet, Inc., Johnson & Johnson, Inc., Medtronic, Inc., Advanced Cell Technology, Inc., Cytomedix, Inc., Arteriocyte Medical Systems, Inc., Athersys, Inc., Bioheart, Inc., Cytori Therapeutics, Inc., International Stem Cell Corporation, Neostem, Inc., Terumo Medical Corporation, Mesoblast, Osiris Therapeutics, Inc., Pluristem, Inc. Stem Cells, Inc. and Tengion, Inc.

Company Address

Aastrom Biosciences Inc

24 FRANKL LLOYD WRIGHT DR,
PO Box 376
ANN ARBOR   MI   48106
P: +1734.9305555
F: +1734.6650485

Company Web Links

Search Stocks